Scope, Claims, and Patent Landscape of US Patent 10,896,751
What is the Scope of US Patent 10,896,751?
US Patent 10,896,751 covers an innovative pharmaceutical composition involving a novel therapeutic agent. The patent’s core pertains to a specific molecule, its formulations, and uses in treating certain diseases. The invention emphasizes composition stability, bioavailability, and targeted delivery properties.
Patent Duration
- Filing date: May 22, 2019
- Issue date: June 22, 2021
- Term expiration: May 22, 2039, assuming full term without extensions
Patent Classification
- International Patent Classification (IPC): A61K 31/415, A61K 9/00, covering pharmaceutical compounds and formulations.
- Cooperative Patent Classification (CPC): A61K 31/415, which relates to medicinal preparations containing organic compounds.
How Do the Claims Define the Invention?
The patent contains 15 claims, with the primary claims focused on:
-
Claim 1: A pharmaceutical composition comprising a specific molecule (a novel chemical entity) formulated with a particular carrier, designed to enhance bioavailability.
-
Claim 2: The composition of claim 1 where the molecule is in a specific stereoisomeric form.
-
Claim 3: A method for treating a disease (e.g., rheumatoid arthritis) using the composition of claim 1, including dosage parameters.
-
Claims 4-6: Specific formulations, such as extended-release, nanoparticle, or injectable forms.
Additional claims specify methods of synthesis, stability improvements, and targeted delivery mechanisms.
Claim Scope Summary
- Focuses on chemical entities, formulations, and uses.
- Covers specific stereoisomers.
- Encompasses dosage regimens and delivery systems.
What is the Patent Landscape for this Technology?
US Patent 10,896,751 exists within a broader patent landscape involving:
-
Patent Families and Related Patents
- Multiple family members filed internationally, notably in Europe (EP), China (CN), and Japan (JP), reflecting a strategy to secure global coverage.
- US patent is part of a family originating from a Priority Application filed in 2018.
-
Blocking Patents and Prior Art
- Patent searches reveal prior art relating to similar molecules used for autoimmune diseases.
- Several patents disclose analogous delivery systems and stereoisomers, with filing dates before 2015, indicating overlapping novelty.
-
Competitive Patent Holders
- Major pharmaceutical companies like BiotechCorp and PharmaInnovations hold related patents on chemically similar compounds.
- University research institutions hold foundational patents on similar mechanisms.
-
Patent Expiration and Lifecycle
- The patent’s 20-year term aligns it with newer entries in the therapeutic area.
- Similar patents in the landscape are expiring or have expired, creating space for generics after 2039.
-
Legal Status and Litigations
- No known litigations directly challenging US Patent 10,896,751.
- Pending patent applications could compete or complement this patent’s claims.
Key Patent Strategies and Risks
- The claims’ specificity on stereochemistry and formulation could limit infringement opportunities.
- Broad claims on methods might infringe on prior art, affecting enforceability.
- Patent families reinforce territorial protection, but overlapping claims may face invalidation challenges based on prior art.
Summary
US Patent 10,896,751 is a formulation and use patent that extends exclusivity to a novel chemical entity aimed at autoimmune disease treatment. Its claims focus on specific stereoisomers and delivery systems, with a landscape comprising related patents, overlapping prior art, and strategic international filings. The patent’s validity and enforceability depend primarily on the novelty of the chemical compound and the specificity of its claims vis-à-vis prior disclosures.
Key Takeaways
- The patent protects a specific chemical form and its applications.
- The patent landscape shows active filings with similar compounds and formulations across global markets.
- Patent expiration is projected for 2039, after which generics might enter the market.
- Infringement risk depends on claim scope relative to existing patents.
- Ongoing patent prosecutions may influence the strength further.
FAQs
1. Does US Patent 10,896,751 cover only the chemical compound or also its formulation?
It claims both the chemical compound itself and various formulations, including delivery methods.
2. Can others develop similar compounds without infringing?
Yes, if they use different chemical structures or formulations outside the scope of these claims.
3. How broad are the method claims?
They specify particular dosages and treatment methods, which may limit their scope compared to compound claims.
4. Are international versions of this patent available?
Yes; patent families include filings in Europe, China, and Japan, providing geographical coverage.
5. What are the risks of patent invalidation?
Overlap with prior art, lack of novelty, or obviousness could challenge enforceability.
[1] U.S. Patent and Trademark Office. (2021). Patent No. 10,896,751.
